92 related articles for article (PubMed ID: 19252847)
1. Anti-CD22 Onconase: preparation and characterization.
Newton DL; Stockwin LH; Rybak SM
Methods Mol Biol; 2009; 525():425-43, xiv. PubMed ID: 19252847
[TBL] [Abstract][Full Text] [Related]
2. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
Weber T; Mavratzas A; Kiesgen S; Haase S; Bötticher B; Exner E; Mier W; Grosse-Hovest L; Jäger D; Arndt MA; Krauss J
J Immunol Res; 2015; 2015():561814. PubMed ID: 26605343
[TBL] [Abstract][Full Text] [Related]
3. Antibody-onconase conjugates: cytotoxicity and intracellular routing.
Rybak SM
Curr Pharm Biotechnol; 2008 Jun; 9(3):226-30. PubMed ID: 18673288
[TBL] [Abstract][Full Text] [Related]
4. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
Newton DL; Hansen HJ; Mikulski SM; Goldenberg DM; Rybak SM
Blood; 2001 Jan; 97(2):528-35. PubMed ID: 11154233
[TBL] [Abstract][Full Text] [Related]
5. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
Krauss J; Arndt MA; Vu BK; Newton DL; Seeber S; Rybak SM
Biochem Biophys Res Commun; 2005 Jun; 331(2):595-602. PubMed ID: 15850802
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review].
Lu PP; Meng ZY; Zhou MX; Wang MW; Dou GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1258-61. PubMed ID: 17204206
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapeutic RNases (ImmunoRNases).
Schirrmann T; Krauss J; Arndt MA; Rybak SM; Dübel S
Expert Opin Biol Ther; 2009 Jan; 9(1):79-95. PubMed ID: 19063695
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.
Stanciu-Herrera C; Morgan C; Herrera L
Leuk Res; 2008 Apr; 32(4):625-32. PubMed ID: 17706771
[TBL] [Abstract][Full Text] [Related]
11. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
O'Donnell RT; Pearson D; McKnight HC; Ma YP; Tuscano JM
Cancer Immunol Immunother; 2009 Oct; 58(10):1715-22. PubMed ID: 19294384
[TBL] [Abstract][Full Text] [Related]
12. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.
Ziaei V; Ghassempour A; Davami F; Azarian B; Behdani M; Dabiri H; Habibi-Anbouhi M
Mol Cell Biochem; 2024 Mar; 479(3):579-590. PubMed ID: 37129769
[TBL] [Abstract][Full Text] [Related]
13. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
Takeshita A; Yamakage N; Shinjo K; Ono T; Hirano I; Nakamura S; Shigeno K; Tobita T; Maekawa M; Kiyoi H; Naoe T; Ohnishi K; Sugimoto Y; Ohno R
Leukemia; 2009 Jul; 23(7):1329-36. PubMed ID: 19369961
[TBL] [Abstract][Full Text] [Related]
14. Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.
Leung SO; Gao K; Wang GY; Cheung BK; Lee KY; Zhao Q; Cheung WT; Wang JZ
MAbs; 2015; 7(1):66-76. PubMed ID: 25427174
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of fully human anti-CD22 monoclonal antibodies.
Xiao X; Ho M; Zhu Z; Pastan I; Dimitrov DS
MAbs; 2009; 1(3):297-303. PubMed ID: 20065646
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
18. Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3.
Sun M; Tang H; Gao Y; Dai X; Yuan Y; Zhang C; Sun D
Oncol Rep; 2016 Apr; 35(4):1987-94. PubMed ID: 26782924
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
Kong Y; Barisone GA; Abuhay M; O'Donnell RT; Buksh Z; Yousefian F; Tuscano JM
Leuk Res; 2014 Nov; 38(11):1320-6. PubMed ID: 25241275
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
